

## ANTIMICROBIAL SUSCEPTIBILITY TRENDS AMONG VIRIDAN STREPTOCOCCI ISOLATES FROM CASES OF ENDOCARDITIS FROM 2011 – 2012

Prabhu N<sup>\*#</sup>, Jeyaseelan Senthinath T<sup>\*</sup>, Joseph Pushpa Innocent D<sup>\*\*</sup>, Lalitha MK<sup>\*\*\*</sup>

<sup>\*</sup>Department of Microbiology and Health Science Research, Chennai Medical College Hospital and Research Centre, Tiruchirapalli – 621 105, India.

<sup>\*\*</sup>Department of Microbiology, Karpaga Vinayaga Institute of Medical Sciences and Research Institute, Madhuranthagam, Kancheepuram, India.

<sup>\*\*\*</sup>Department of Microbiology, Madras Medical Mission, Mogappair, Chennai, India.

### ARTICLE INFO

#### Corresponding Author:

Prabhu N,  
Department of Microbiology and  
Health Science Research, Chennai  
Medical College Hospital and  
Research Centre, Tiruchirapalli –  
621 105, India.

**Keywords:** Viridans streptococci –  
endocarditis – antibiogram

### ABSTRACT

To determine the changes found in antimicrobial resistant character occurred among viridans groups of streptococci, this study examined 30 viridans group streptococci isolated from infective endocarditis patients. The isolation patterns revealed based on biochemical identification as four viridans streptococcal species groups – *mitis*, *mutans*, *salivarius* and *sanguinis*. Resistance rates of the isolates were as follows, Penicillin – 2; Clindamycin – 2; Erythromycin – 5; Azithromycin – 10; Vancomycin – 4; Levofloxacin – 1 and Ciprofloxacin – 2.

©2013, IJMHS, All Right Reserved

### INTRODUCTION

The observation of Bacteremia episodes due to viridans group of streptococci found 20 – 40% in neutropenic patients<sup>1,2,3,4</sup> and 30 – 40% of infective endocarditis cases<sup>5</sup>. In hematologic patients, fluoroquinolones are used as antibacterial prophylaxis agents during the neutropenic period after haematopoietic stem cell transplantation or chemotherapy alone<sup>6</sup>. Many case studies highlighted the episodes of bacteremia with fluoroquinolone resistant viridans group streptococci during fluoroquinolone prophylaxis<sup>7,8</sup>. Previous study reported 16% rate of this problem with fluoroquinolone resistant viridans group streptococci during Levofloxacin prophylaxis in hematology patients undergoing autologous stem cell transplantation<sup>6</sup>. In recent years, several case reports of infective endocarditis due to penicillin resistant viridans group streptococci have been published<sup>9-13</sup>. By taking the research of above said as reference, we retrospectively examined antimicrobial susceptibility trends, including fluoroquinolone susceptibility, in a collection of viridans group streptococcal isolates spanning 5 years, to see if changes found in antimicrobial resistance had occurred.

### MATERIALS & METHODS

The selected blood samples from bacterial endocarditis patients have been collected from tertiary care hospitals of Thanjavur district with proper institutional ethical clearance and processed bacteriologically. The cultural patterns were biochemically identified and classified according to the criteria set forth by Focklam<sup>14</sup>. 30 isolates collected from 2001 – 2005 were included in this study. These isolated organism have clinically relevance from the

antimicrobial susceptibility perspective because they are of proven pathogenic potential in immuno competent hosts, MICs were determined by broth microdilution in cation adjusted Mueller Hinton broth supplemented with 2.5% lysed horse blood and interpreted according to NCCLS guidelines<sup>15,16</sup>. The concentration ranges tested were 0.125 to 128 g/ml (in doubling dilutions) for Penicillin, Clindamycin, Erythromycin, Azithromycin, Vancomycin, Levofloxacin, Ciprofloxacin. Till now NCCLS has not published susceptibility break points for quinolone – Ciprofloxacin included in this study.

### RESULTS & DISCUSSION

Due to the initial identification data of many of the isolated, they were biochemically identified and classified into 4 viridans streptococcal species groups like *mitis*, *mutans*, *salivarius* and *sanguinis*. The confirmation of eh analysis is mainly through the performance tests on commonly used reagents. Streptococcus mitis is confirmed by optocin negative (resistant) on blood agar whereas *S. mutans* is optocin positive (susceptible). Among the isolates from 2001 – 2005, monobacterial isolation found in 12 cases (n=30) and polybacterial found in 19 cases and one found to be lost. In monobacterial analysis, *S. mitis* place top in 7 cases followed by *S. mutans*, *S. salivarius* and *S. sanguinis* in 2, 1 and 2 cases respectively. Among polybacterial studies (n=19), *S. mitis* and *S. mutans* mixture is in top of 10 cases followed by *S. mitis*, *S. mutans* and *S. salivarius* mixture; *S. mitis* and *S. sanguinis* mixture and *S. mitis*, *S. mutans* and *S. sanguinis* in 4, 2 and 3 respectively.

In isolates from 2011 – 2012, high rates of resistancy were measured to Azithromycin (33%), Erythromycin (17%) and Vancomycin (13%). The lowest rates of non susceptibility were those to Ciprofloxacin (7%), Clindamycin (7%), Levofloxacin (3%) and Penicillin (7%). In this study, higher MIC were found for Ciprofloxacin (8 g/ml) and Levofloxacin (8 g/ml) supported some other studies<sup>17</sup>. In contrast, the level of penicillin non susceptibility among the isolates (3%) was lower than the report in recent surveillance blood culture studies<sup>17-19</sup>. Two of our isolates (one of *S. mitis* and one of *S. sanguinis* were penicillin non susceptible. The elvel of Azithromycin (33%) and Erythromycin (17%) resistancy among isolates in our study was comparable to previous studies<sup>17-19</sup>.

For the four vancomycin resistance viridans group streptococci isolates in the present investigation, the MICs were 2 g/ml and within the margin of the assay<sup>16</sup>. There have been previous reports of viridans group streptococci for which vancomycin MICs were slightly elevated<sup>20,21</sup>. There are some limitations in our study,

1. Sample size is small, so did not provide the power to detect statistical significance differences.
2. Viridans group of streptococci isolates were from tertiary care centre also may not be reflective of endocarditis isolates seen in community hospital.
3. The isolates from patients population include in this study are recovered may influence antimicrobial susceptibility patterns, isolated from endocarditis patients may not reflect the fluoroquinonoe – ciprofloxacin susceptible pattern. Some studies showed the trend to reducing susceptibility to ciprofloxacin in patients with a diagnosis of cancer verses those without such diagnosis<sup>17</sup>.
4. The antimicrobial therapeutical history of these patients was unknown, a needful factor which may have influenced antimicrobial susceptibility.
5. Not all viridans group streptococcal strains were archived from endocarditis patients diagnosed during the time period of this study resulting in the level of non susceptibility reported in the context of these limitations.
6. Larger prospective surveillance studies are needed to monitor antimicrobial resistance in viridans group streptococci

From defined patient populations such as neutropenic hematology and endocarditis patients.

This is one of the novel studies of reporting antimicrobial susceptibility patterns of viridans group of streptococci based on clinical diagnosis. From this study, we come to conclusion that increasing levels of antimicrobial resistance could impact the rate of bacteremia with viridans group streptococci in neutropenic patients receiving fluoroquinone prophylaxis and may not influence antimicrobial prevention and management of infective endocarditis.

## REFERENCES

1. Bochud PY, Eggiman P, Calandra T, Ven Melle G, Saghafi L, and Francioli P, Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. *Clin. Infect. Dis*, 1994, vol 18, pp 25-31.
2. Brown ER, Wheat JL, Kneebone PH, Sundbland K, Hromas RA, and Tricot G, Randomized trial of the addition of gem positive prophylaxis to standard

antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. *Antimicrob. Agents. Chemother*, 1994, vol 8, pp 576-579.

3. Donnelly JP, Dompelling EC, Meis JF, and de Pauw BE, Bacteremia due to oral viridans streptococci in neutropenic patients with cancer; cytostatics are a more important risk factor than antibacterial prophylaxis. *Clin. Infect. Dis*, 1995, vol 20, pp 469-470.
4. Haahr V, Peterslund NA, and Moller JK, The influence of antimicrobial prophylaxis on the microbial and clinical findings in patients after autologous bone marrow transplantation. *Scand. J. Infect. Dis* 1997, vol 29 pp 623-626.
5. Bayer AS, and Scheld WM, Endocarditis and intravascular infections, p.857 – 884. In G. L. Mandell, J. E. Bennett and R. Dolin (ed.), *Principles and practice of infectious diseases*, 5<sup>th</sup> ed. Churchill Livingstone, Inc., New York, 2000.
6. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, and Patel R, Bacteremia due to vridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. *Clin. Infect. Dis*, 2002, vol 34, pp 1469 – 1474.
7. Classen DC, Burke JP, Ford CD, Evershed S, Aloia MR, Wilfahrt JK, and Elliott JA, Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. *Am. J. Med*, 1990, vol 89, pp 441 – 446.
8. Elting LS, Bodey GP, and Keefe BH, Septecimia and shock syndrome due to viridans streptococci: a case – control study of predisposing factors. *Clin. Infect. Dis*, 1992, vol 14, pp 1201 – 1207.
9. Hall GE, and Baddour LM, Apparent failure of endocariditis prophylaxis caused by penicillin resistant Streptococcus mitis. *Am. J. Med. Sci*, 2002, vol 324, pp 51-53.
10. Levitz RE, Prosthetic-valve endocarditis caused by penicillium resistant Streptococcus mitis. *N. Engl. J. Med*, 1999, vol 340 pp 1843-1844.
11. Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, and Lucey DR, Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. *Clin. Infect. Dis*, 2001, vol 33, pp 577-579.
12. Lonks JR, Dickinson BP, and Runarsdottis V, Endocarditis due to Streptococcus mitis with high level resistance to penicillin and ceotaxime. *N. Engl. J. Med*, 1999, vol 341, pp 1239 – 1241.
13. Sabeela C, Murphy D, and Drummond- Webb J, Endocarditis due to Streptococcus mitis with high level resistance to penicillin and Ceftriaxone. *JAMA*, 2001, vol 285, pp 2195 - 2197.
14. Folklam R, What happen to the streptococci: overview of taxonomic and nomenclature changes. *Clin. Microbiol. Rev*, 2002, vol 15 pp 613-630.
15. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility tests for bacteria that grows aerobically, approved standard, 6<sup>th</sup> ed. M7 – A6. National Committee for Clinical laboratory standards, Wayne, Pa.
16. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility testing; 12<sup>th</sup> informational supplement. MS100-S12.

**Prabhu et.al/ Antimicrobial Susceptibility Trends Among Viridan Streptococci Isolates From Cases Of Endocarditis From 2011 – 2012**

National Committee for Clinical laboratory standards, Wayne, Pa.

17. Dekema DJ, Beach ML, Pfaller MA, Jones RN, and Sentry participants group, Antimicrobial resistance in viridans group streptococci among patients without the diagnosis of cancer in the USA, Canada and Latin America. *Clin. Microbiol. Infect*, 2002, vol 7 pp 152-157.
18. de Azavedo JC, Trpeski L, Pong-Porter S, Matsumura S, and Low DE, In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada. *Antimicrob. Agents. Chemother*, 1999, vol 43, pp 2299-2301.
19. Doern GV, Ferraro MJ, Brueggemann AB, and Ruoff KL, Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United states. *Antimicrob. Agents. Chemother*, 1996, vol 40, pp 891-894.
20. Rolston KV, Elting LS, and Bodey GP, Bacteremia due to viridans streptococci in neutropenic patients. *Am. J. Med* 1995, vol 99, pp 450 - 451.
21. Spanik S, Trupl J, Kunova A, Botck R, Sorkovska D, Grey E, Srudena M, Lacka J, Oravcova E, Krchnakova A, Svec J, Krupova I, Grausova S, Stopkova K, Koren P, and Kremery V, Viridans streptococcal bacteremia due to penicillin resistant and penicillin sensitive streptococci; analysis of risk factors and outcome in 60 patients for a single cancer centre before and after penicillin is used for prophylaxis. *Scan. J. Infect. Dis*, 1997, vol 29, pp 245-249.